W.B. Saunders for the American Gastroenterological Association
Clinical Gastroenterology and Hepatology vol:13 issue:3 pages:531-8
Infliximab is effective for patients with refractory ulcerative colitis (UC), but few factors have been identified that predict long-term outcome of therapy. We aimed to identify a panel of markers associated with outcome of infliximab therapy to help physicians make personalized treatment decisions.